1. Fukuoka Y., Ikeda Y., Yamashiro Y., Todo Y., Narita H. (1993): In vitro and in vivo antibacterial activities of T-3761, a new quinolone. Antimicrob. Agents Chemother., 37: 384–392.
2. Yongxia B., Yuxia S., Fuzhen L. (2005): Clinical randomized controlled trials of pazufloxacin for injection in the treatment of respiratory tract and urinary tract bacterial infections. China J. Antibiotics, 30: 624–628.
3. Sugihara T., Yoshida T., Minagawa H. (2000): Clinical study of pazufloxacin mesilate, a new quinolone antibacterial agent, in burn infections and tissue concentrations. Jpn J. Chemother., 48: 401–405.
4. Nomura N., Mitsuyama J., Furuta Y. (2002): In vitro andin vivo antibacterial activity of pazufloxacin mesilate, a new injectable quinolone. Japan J. Antibiot., 55: 412–419.
5. Shimada K. (2002): Optimal clinical dose of pazufloxacin mesilate in respiratory tract infection or complicated urinary tract infection. Japan J. Chemother., 50: 435–441.